 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...8990919293949596979899...235236» |
- ||| Clinical, Adverse events, Circulating tumor DNA: If a stage 2 patient is told they have a 100% chance to progress to st IV being #ctDNA +ve, the pt maybe OK with FOLFOXIRI & it's side-effects for a chance at cure? Unless of course a liver MRI finds a met, which can now be resected & that hopefully makes them ctDNA-ve. (Twitter) - Jun 4, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: A bit surprised no one is using volumetric constraints for hollow viscera based on Stanford data Timmerman constraints as used in Dutch ph II study of FOLFIRINOX --> SBRT (8 Gy x 5, stomach Dmax 35 Gy) --> crude ≥gr 3 GI tox 10.3%, 2/39 pts with fatal GI bleed (Twitter) - Jun 4, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Secondary endpoint of FIRE-4 @ASCO. Switch maintenance to 5Fu/Bev after FOLFIRI/Cetux in 1st line CRC does not improve mPFS. Expected?! (Twitter) - Jun 4, 2022
- ||||| Clinical: NIVACOR trail @ASCO Abstr. 3509, first efficacy and safety data for FOLFOXIRI/bevacizumab + Nivolumab in 1st line mutant BRAF/RAS CRC ORR 76.7%, mPFS 10.1 months, interesting, but… #CRC #immuntherapy (Twitter) - Jun 4, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Rapid fire: 1) PhI/Ib CLDN 18.2 #CAR-T in adv #stcsm +proof of principle but ORR short-lasting, 2) PhII RCT of neoadj #CROSS vs FOLFOX-RT in resectable #esocsm higher R0 w/CROSS but FOLFOX w/less periop complications ?FOLFOX new alt, 3) role anti-EGFR + chemoRT in #ESCC #ASCO22 (Twitter) - Jun 4, 2022
- |||| Clinical, Circulating tumor DNA: I just had this convo! I would like to know the answer too! Why not test all stage II Colon cancer pts & offer chemo only to those ctDNA+. The CIRCULATE-US trial will tell us if FOLFOXIRI is better at clearing ctDNA than FOLFOX Pts are already getting tested anyways. #ASCO22 (Twitter) - Jun 4, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless? (Pubmed Central) - Jun 4, 2022
Our results suggest that NAT may lower PALN involvement. We have modified our policy, positive PALN after NAT are no longer a contraindication to resection, rather a holistic picture of the disease guides management.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis. (Pubmed Central) - Jun 4, 2022
Patients who received adjuvant chemotherapy based on 5-FU/LV showed comparable oncologic outcomes to patients in the OB group even after stratification by tumor stage. The patients with intestinal subtype showed oncologic benefit for adjuvant 5-FU/LV CTx compared with pancreatobiliary or mixed subtypes.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
P2 data, Journal: Results of a Phase II Study on the use of Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine with nab-paclitaxel) for Borderline-Resectable Pancreatic Cancer (NUPAT-01). (Pubmed Central) - Jun 4, 2022
These results indicate that neoadjuvant chemotherapy with FOLFIRINOX or GEM/nab-PTX is feasible and well tolerated, achieving an R0 resection rate of 67.4%. The survival of patients was even found to be favorable in the intention-to-treat analysis.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: I got 3m of CAPOX, thanks to Dr. Grem,& don't have neuropathy. I do have some chemo brain& I shudder to think how bad it could have been, had I got 6m of FOLFOX Less chemo for those who don't need it is a great improvement in care for the ~80% #CRC pts who r early stage! #ASCO22 (Twitter) - Jun 4, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Great thread from Dr @marklewismd 5 y ago this time, I had a port placed for what I thought would be 6 months of FOLFOX. The 1st results of the IDEA trial were out at the 2017 #ASCO & I didn't want 6m chemo if 3m was good enough for my upper rectal cancer #ASCO22 #CRCSM (Twitter) - Jun 4, 2022
- |||| Clinical: Atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and irinotecan resulted in a tolerable safety profile and improved progression-free survival vs the control regimen in patients with metastatic colorectal cancer. #crcsm | @ChiaraCrem1 https://t.co/BXxUlujgHa (Twitter) - Jun 4, 2022
- ||||||| Clinical, P1 data, Combination therapy: #CedarsSinaiCancer at #ASCO22. @DrHendifar is co-author on “Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI & bevacizumab in second-line advanced #ColorectalCancer.” @ASCO @CedarsSinaiMed @CSCancerCare (Twitter) - Jun 4, 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma. (Pubmed Central) - Jun 4, 2022
Group I received AVCF (doxorubicin, vinorelbine, cyclophosphamide, FUra, FA) or FAC (doxorubicin, cyclophosphamide, FUra, FA) followed by TCbF (paclitaxel carboplatin, FUra, FA)...Group II also received trastuzumab and pertuzumab...Unexpected toxicity did not occur. This pilot study suggests that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA.
- || Tedopi (OSE 2101) / OSE Immunotherapeutics, 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
But TEDOPI/OSE2101 boost FOLFIRI (Twitter) - Jun 4, 2022
- | Rubraca (rucaparib) / Pharma& Schweiz, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial primary completion date, Metastases: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (clinicaltrials.gov) - Jun 3, 2022
P2, N=18, Recruiting, Sponsor: Academic and Community Cancer Research United
This pilot study suggests that high-dose vitamin B6 enhances antitumor potency of regimens comprising FUra and FA. Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Aug 2023
- || leucovorin calcium / Generic mfg.
Omg the word was leucovorin! #GIonc 🤓 https://t.co/dOq7aRfVHs (Twitter) - Jun 2, 2022
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Effects Of Exercise Dose On Chemotherapy Induced Physical Dysfunction In Male Mice () - Jun 2, 2022 - Abstract #ACSM2022ACSM_3114;
Two weeks of low-dose treadmill exercise was sufficient to reverse chemotherapy induced fatigue without altering deficits in strength. Future studies should examine if the combined effects of aerobic and resistance exercise can improve strength.Acknowledgements: NCI R21-CA231131
- |||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial primary completion date: TRIPLET-III: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (clinicaltrials.gov) - Jun 2, 2022
P3, N=140, Recruiting, Sponsor: Sun Yat-sen University
Future studies should examine if the combined effects of aerobic and resistance exercise can improve strength.Acknowledgements: NCI R21-CA231131 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Nov 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Trial completion date: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Jun 1, 2022
P2, N=25, Completed, Sponsor: Brown University
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Nov 2024 Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2022
- |||| magrolimab (ONO-7913) / Ono Pharma
Enrollment open, Combination therapy, Metastases: ELEVATE CRC: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jun 1, 2022
P2, N=215, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2022 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: FOLRT: Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - May 31, 2022
P2, N=50, Active, not recruiting, Sponsor: Campus Bio-Medico University
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: #ASCO22 #PancreaticCancer 🤔Is more better❓ ✅Dr. Carrato🧑🏫a Rand trial 👉Gem-nab-pac➡️FOLFOX (sequenced Q6 wks) vs. 👉Standard Gem-nab-pac ➡️mOS was 3.5mos⬆️with sequenced Tx ➡️Even though more standard pts got 2nd line Tx 🤯Really❓ 🤔Interesting 🔎GI Can Oral Abst 4022 (Twitter) - May 31, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Older trial run in the preFOLFIRINOX era. No benefit in primarily resectable PDAC. Also, based on the design of the ongoing PREOPANC-3, the results of PREOPANC-2 must have been negative for CRT compared to FOLFIRINOX. We need to accept that RT plays a very minor role in PDAC. (Twitter) - May 31, 2022
- | Enrollment change: Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99) (clinicaltrials.gov) - May 31, 2022
P3, N=885, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting --> Recruiting N=400 --> 885
- ||||| Clinical: Phase 2 study shows that addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab improves progression-free survival in patients with metastatic colorectal cancer: https://t.co/8u9V2VuWDy @TheLancetOncol @ChiaraCrem1 #Immunotherapy #oncotwitter #MedTwitter #oncology (Twitter) - May 31, 2022
- | Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI (clinicaltrials.gov) - May 31, 2022
P1, N=14, Completed, Sponsor: University of Massachusetts, Worcester
N=400 --> 885 Recruiting --> Completed | Trial completion date: Sep 2023 --> Feb 2022 | Trial primary completion date: Aug 2023 --> Feb 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients. (Pubmed Central) - May 31, 2022
There is no significant harm on the risk of death when reducing RDI by <30% for high-risk patients. For the low-risk patients, we found that RDI as low as 45% did not significantly affect the risk of death.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal, HEOR: Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. (Pubmed Central) - May 31, 2022
Our study shows that no relevant impairment of patients HRQoL between the 2 treatment arms. So, the analysis of the HRQoL with equal effectiveness does not make it possible to favor one treatment over another.
- | Journal: Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer. (Pubmed Central) - May 31, 2022
In patients with oligoprogressive or oligopersistent mCRC, MRT may be performed safely in conjunction with systemic treatment to maximize the benefit of systemic therapy and to prolong the time to change to systemic therapy. Further prospective studies should confirm these findings.
- || leucovorin calcium / Generic mfg.
Clinical, P1 data, Journal: Immediate Adjuvant Chemotherapy in Non-Metastatic Colon Cancer: Phase I Trial Evaluating a Novel Treatment Protocol. (Pubmed Central) - May 31, 2022
A protocol based on IAC starting at the time of surgical resection was found to be safe and feasible with no adverse effects on surgical morbidity or quality of life. Further prospective studies are needed to explore the oncologic benefit of this novel systemic treatment approach.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined. (Pubmed Central) - May 31, 2022
Further prospective studies are needed to explore the oncologic benefit of this novel systemic treatment approach. No abstract available
- || gevokizumab (VPM087) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov) - May 31, 2022
P1, N=172, Recruiting, Sponsor: Novartis Pharmaceuticals
No abstract available Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Jan 2023
- | Enrollment open, Metastases: Redefining FOLFIORINOX in Older Pancreatic Cancer Patients (clinicaltrials.gov) - May 30, 2022
P2, N=37, Recruiting, Sponsor: Fox Chase Cancer Center
Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Nov 2023 --> Jan 2023 Not yet recruiting --> Recruiting
- || tremelimumab (CP-675206) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
P2 data, Journal: Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. (Pubmed Central) - May 30, 2022
However, the Independent Data Monitoring Committee recommended brain imaging at inclusion. This safety run-in phase demonstrates an expected safety profile of FOLFIRI with Durvalumab +/- Tremelimumab combination allowing the randomised phase II.
- || gemcitabine / Generic mfg.
Review, Journal: Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. (Pubmed Central) - May 30, 2022
While the FOLFIRINOX scheme has a slightly longer overall survival, it also produces many more adverse eventsso that gemcitabine is still considered the first choice for treatment, especially in combination with other compounds/agents. This review discusses the multiple causes of gemcitabine resistance in PDAC.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., tegafur/uracil / Generic mfg.
Journal: Tegafur-Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally Advanced Rectal Cancer. (Pubmed Central) - May 30, 2022
The toxicity, complications, and surgical outcomes are similar to those of mFOLFOX-6. Thus, TEGAFOX can be considered a chemotherapy option for rectal cancer treatment.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: Interesting facts and not surprising that CAPOX is preferred in rural India. Definitely much easier to administer than FOLFOX. The large >12,000 patients in the IDEA trial showed that CAPOX was marginally better than FOLFOX. CAPOX has more toxicity (elderly and elevated GFR) (Twitter) - May 29, 2022
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Retrospective data, Journal: Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French Group of Endocrine Tumors (GTE). (Pubmed Central) - May 29, 2022
FOLFOX shows a promising antitumor activity in advanced digestive NETs. Rapid symptomatic response is observed in metastatic insulinomas.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: This patient would go on to complete surgery 7 weeks post-SBRT. Results: 1.2 cm residual, treatment effect noted. Negative margins. 4/18 nodes positive. Completed 2 additional months of FOLFIRINOX. (Twitter) - May 28, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Head-to-Head: While we're at it, the goal for BR-PDAC is to get them to surgical resection. How do we reconcile XRT with 21501 and the superiority of FOLFIRINOX x 8? No one believes FOLFIRINOX x 8 will lose to 36 Gy/15 + GEM. So why/when should we add XRT? (Twitter) - May 28, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Before we talk about Jang, I'll confess I was apoplectic when 21501 was presented at ASCO. RO folfirinox x 8 >> FOLFIRINOX x 7 plus SBRT, OS >>>>as well. (Twitter) - May 28, 2022
- ||||| Clinical: 🎙Now out in @TheLancetOncol: AtezoTRIBE RCT on FOLFOXIRI/bev & atezo in #crcsm 👩🏻🏫Promising strategy for pMMR 👩🏻💻Immunoscore IC by @JeromeGalon as predictor to select immune hot tumors 💞Tnx @ChiaraCrem1 @FilippoPietran4 @LisaSalvy @SaraLonardi1 & patients https://t.co/iHdE3pPNzO (Twitter) - May 28, 2022
- |||| Clinical, P3 data: 🏅🏅#ASCO22BRACKET🏅🏅 Vote here for your most anticipated #ASCO22 abstract 👇🏼 👇🏼 1) Phase 3 PARADIGM: Pani+mFOLFOX6 versus bev+mFOLFOX6 1: RAS WT mCRC 2) DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in pts with HER2-low mBC (Twitter) - May 27, 2022
- | Trial primary completion date: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 27, 2022
P2, N=9, Active, not recruiting, Sponsor: Yale University
Rapid symptomatic response is observed in metastatic insulinomas. Trial primary completion date: Feb 2022 --> Aug 2022
- | Retrospective data, Journal: Time to Neoadjuvant Chemotherapy Initiation is not Associated With Survival in Pancreatic Cancer. (Pubmed Central) - May 27, 2022
Delay in NAC initiation for PDAC is not associated with survival. Patient optimization could be considered with the goal of improving tolerance of multiagent chemotherapy.
- ||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - May 26, 2022
P2, N=58, Recruiting, Sponsor: National Cheng-Kung University Hospital
Patient optimization could be considered with the goal of improving tolerance of multiagent chemotherapy. Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. (Pubmed Central) - May 26, 2022
Not yet recruiting --> Recruiting The Paraconsistent Value Framework is proposed as a step beyond the current MCDA practices, in order to improve means of dealing with individual expert perspectives in hospital-based HTA of cancer treatments.
- || Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
New P1/2 trial: REGONIVOCTx: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (clinicaltrials.gov) - May 26, 2022
P1/2, N=36, Not yet recruiting, Sponsor: National Cancer Center Hospital East